Abstract 1846P
Background
Confronting breast cancer diagnosis, alongside with complex and challenging treatment procedures comprise an extremely stressful experience. Psychological resilience (PR) is the ability to maintain or restore normal functioning while facing the adversity, leading to better quality of life and preventing stress-related health conditions in cancer patients. We aimed to investigate the impact of early breast cancer (EBC) diagnosis on PR, distress and perception of health.
Methods
Case-controlled study included 50 newly diagnosed EBC patients and 67 women without breast cancer whose screening mammography was graded by Breast imaging-reporting and data system 1 and 2. The level of distress, perception of health and PR were assessed using the Depression Anxiety and Stress Scale 21, SF 36-Item Health Survey 1.0 and Connor-Davidson RISC-25 scale. EBC patients were questioned after confronting EBC diagnosis and before starting the treatment.
Results
The EBC patients reported deterioration of health, compared to previous year (t (df) 3,835, p<0.01), while there were no differences between groups related to general and emotional health. There was no significant statistical difference between groups regarding the levels of depression, anxiety and stress. Majority of the EBC patients and controls, 66% and 82%, had no symptoms of depression, while severe depression was noted in 10% and 3%, respectively. Around 78% EBC patients and 89% controls didn't show any anxiety. Still, 8% EBC patients and 4.5% controls were severely anxious, and 10% EBC and 4% controls were severely stressed. And finally, regarding resilience, EBC patients showed significantly higher levels of PR than healthy control (t(df) 2,530, p<0.05).
Conclusions
Confronting EBC diagnosis, possibly leads to activation of intra-individual coping mechanisms and dynamic processes of effective adaptation leading to higher PR levels of EBC patients compared with healthy controls. Further research of PR should be encouraged, by investigating the mechanisms that protect individuals and prevent stress-related health conditions, resilience research shifts a paradigm from a disease-oriented to health-oriented and focuses on mechanisms that prevent stress-related disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05